4.3 Review

NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes

Journal

PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
Volume 116, Issue 2-3, Pages 101-112

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pbiomolbio.2014.08.012

Keywords

Structure-based lead discovery; NMR fragment screening; Hit-to-lead optimization; Protein-protein interactions; Multi-protein complexes; Protein expression

Funding

  1. UK Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J001201/1, BB/G023123/1]
  2. European Research Council [ERC-2012-StG-311460]
  3. European Commission (Bio-NMR) [261863]
  4. Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/81735/2011]
  5. BBSRC [BB/G023123/2, BB/J001201/2, BB/G023123/1, BB/J001201/1] Funding Source: UKRI
  6. Biotechnology and Biological Sciences Research Council [BB/G023123/1, BB/J001201/2, BB/J001201/1, BB/G023123/2] Funding Source: researchfish
  7. Fundação para a Ciência e a Tecnologia [SFRH/BD/81735/2011] Funding Source: FCT

Ask authors/readers for more resources

Nuclear magnetic resonance (NMR) spectroscopy is a pivotal method for structure-based and fragment-based lead discovery because it is one of the most robust techniques to provide information on protein structure, dynamics and interaction at an atomic level in solution. Nowadays, in most ligand screening cascades, NMR-based methods are applied to identify and structurally validate small molecule binding. These can be high-throughput and are often used synergistically with other biophysical assays. Here, we describe current state-of-the-art in the portfolio of available NMR-based experiments that are used to aid early-stage lead discovery. We then focus on multi-protein complexes as targets and how NMR spectroscopy allows studying of interactions within the high molecular weight assemblies that make up a vast fraction of the yet untargeted proteome. Finally, we give our perspective on how currently available methods could build an improved strategy for drug discovery against such challenging targets. (C) 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available